行情

MREO

MREO

MEREO BIOPHARMA
NASDAQ

实时行情|Nasdaq Last Sale

2.175
+0.015
+0.69%
休市 16:00 01/17 EST
开盘
2.160
昨收
2.160
最高
2.280
最低
2.160
成交量
10.19万
成交额
--
52周最高
8.48
52周最低
1.080
市值
4,729.97万
市盈率(TTM)
-0.9977
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MREO 新闻

  • WEF报告:全球一半的GDP适度或高度依赖大自然
  • 第一财经.4小时前
  • 刘强东:京东员工已超21万人 CHO正牵头制定京东家法
  • 澎湃新闻.4小时前
  • 世界首富又易主!LV总裁挤掉亚马逊创始人登顶榜首
  • 新浪财经综合.6小时前
  • 一个时代的终结? 二十世纪福克斯电影公司改名了
  • 中国新闻网.7小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

MREO 简况

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on development and commercialization of therapeutics for patients with rare diseases. Its pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab. BPS-804 (setrusumab) is being developed to improve bone strength and thereby reduce fractures in the orphan disease osteogenesis imperfecta (OI). MPH-966 (alvelestat) is being developed for alpha-1 antitrypsin deficiency (AATD). BGS-649 (leflutrozole) is being developed for the treatment of obese men with hypogonadotropic hypogonadism (HH). BCT-197 (acumapimod) is being developed as a therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Navicixizumab is being developed for platinum-resistant ovarian cancer. Etigilimab is being developed for advanced or metastatic solid tumors.
展开

Webull提供Mereo BioPharma Group PLC的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。